6 Cheapest Ways to Get Wegovy Without Insurance in 2026

How much does Wegovy actually cost without insurance right now?

The number that circulates most is the list price: about $1,349 a month, whether you're on the pen or the tablet. That's the sticker figure Novo Nordisk sets before any program touches it — the starting point for insurance negotiations, not a price any of the six paths below actually charges you. Almost nobody without insurance pays that number, and you shouldn't either.

What you actually pay depends on which door you walk through. Novo Nordisk's own self-pay program is the reported floor for brand-name Wegovy, worth confirming is live before you count on it. GoodRx, as of this year, appears to largely mirror that same price rather than adding its own discount. And compounded semaglutide — a different, non-Wegovy product built on the same active molecule — runs lower still through a telehealth provider. The rest of this page walks through each, in order of what it actually costs you.

Insurance denied Wegovy? You're not stuck at retail, and you're not in a worse tier either

This is the part that gets muddled online, so it's worth being precise. Novo Nordisk runs two separate programs, and which one applies to you depends entirely on whether your plan covers Wegovy — not on whether you have insurance at all.

• Your plan covers Wegovy: you qualify for the Commercial Copay Savings Offer, capped at $25 a month, up to $100 off a one-month fill.
• Your plan doesn't cover Wegovy — denied, excluded, or you never bothered to check: you use the Wegovy Self-Pay Offer, the same program a fully uninsured woman uses.
• No insurance at all: identical Self-Pay Offer, identical pricing.
• There is no separate, marked-up tier for 'has insurance but it said no.' You fall straight into the general self-pay ladder — tablet from $149/mo, pen from $199/mo introductory, pending confirmation these self-pay tiers are current.

That's genuinely good news if you've been assuming a denial letter locks you into the $1,349 retail number. It doesn't. The gap you actually need to close isn't between 'insured' and 'uninsured' — it's between the $25 covered tier and the self-pay tier, and the self-pay tier is a lot closer to $25 than it is to retail. For the full mechanics of the $25 card itself, including how to check whether your plan covers Wegovy in the first place, see Wegovy savings programs.

NovoCare self-pay: the manufacturer's own program, and the best without-insurance price

NovoCare Pharmacy is Novo Nordisk selling directly to you — no telehealth membership fee layered on top, no third-party markup. You still need a prescription from your own doctor or a telehealth provider; NovoCare is the pharmacy and pricing layer, not the medical visit.

The tablet, approved in December 2025 as the first oral GLP-1 for weight management, is reportedly the cheaper starting point: $149 a month at the 1.5mg and 4mg doses. That 4mg rate is promotional and said to run through the end of August 2026; after that it steps to $199 a month, with the higher 9mg and 25mg strengths priced at $299 a month. The pen carries a $199-a-month introductory rate for your first two fills — through the end of 2026 — then settles at $349 a month for the standard dose range or $399 a month at the highest HD strength.

What NovoCare doesn't include is the clinician relationship. If you don't already have a prescriber, you'll need one before this pricing does you any good — a telehealth intake typically takes a few days, not weeks.

GoodRx: no longer a discount card here, more of a mirror

GoodRx's role with Wegovy appears to have changed from what you might remember with other drugs. Rather than negotiating its own separate discount, GoodRx now appears to surface Novo Nordisk's cash price directly at more than 70,000 pharmacies — the same $149-a-month pill and $199-then-$349-a-month pen you'd get going straight to NovoCare. That's a real shift from the older pattern of GoodRx running meaningfully cheaper or more expensive than the manufacturer's own number, and it's worth double-checking against the current live price before treating it as settled — this figure differs from what's shown on some of our other Wegovy pages, which is flagged for reconciliation.

Practically, this means GoodRx is worth checking if you'd rather pick up your prescription at a local pharmacy than wait on mail order, or if you already have a GoodRx account and app set up. Check both NovoCare and GoodRx directly rather than assuming one beats the other.

Compounded semaglutide: the cash-pay floor, and a different product from Wegovy

Below NovoCare's self-pay price sits compounded semaglutide — the same active molecule, prepared by a licensed 503A pharmacy for an individual patient rather than manufactured and FDA-approved as a finished drug by Novo Nordisk. The legal ground here narrowed through 2025 and into 2026: broad compounding tied to the old drug-shortage exemption ended once semaglutide came off the FDA's shortage list, and the FDA has since sent warning letters to non-compliant sellers. What remains legal is a 503A pharmacy compounding for a specific patient under a valid prescription — which is the model each of the three providers below operates under.

Henry Meds — flat all-in price, oral or injectable

Henry Meds bundles the medication, provider visits, and shipping into one number with no separate membership fee: $249 a month for oral compounded semaglutide, $297 a month for the injection. Neither price rises as your dose does, which matters — some competitors quietly charge more once you're titrated up. Plans are month-to-month with no minimum commitment. The trade-off: labs aren't included, and you'll need to arrange bloodwork separately. As with the other two options below, this is compounded semaglutide from a 503A pharmacy, not FDA-approved Wegovy.

Fridays — cheapest if you can commit to a year

Fridays' month-to-month rate, around $249, lands close to Henry Meds. Where Fridays pulls ahead is the annual plan, which drops to roughly $150 a month and bundles in dietitian access, group coaching, and 24/7 messaging that Henry Meds sells more bare-bones. The honest caveat: that annual rate requires prepaying upfront, and Fridays' BBB profile shows a recurring pattern of complaints about refund difficulty if you need to exit early. If you're confident you'll stay the course, it's the lowest verified all-in price on this page. If you're not sure yet, start month-to-month. Like Henry Meds, this is compounded 503A semaglutide, not the branded drug.

Mochi Health — flat pricing across doses, membership on top

Mochi Health separates the medication from the membership: $99 a month for compounded semaglutide, plus a $79-a-month membership, for about $178 all-in. Like Henry Meds, the price doesn't climb as you titrate up. Mochi requires its physicians to hold obesity-medicine board certification, which is a genuine differentiator if you want a clinician who specializes specifically in weight regulation rather than general primary care. This too is compounded 503A semaglutide rather than FDA-approved Wegovy.

Wegovy pill vs. pen: does the without-insurance price differ by form?

Yes, meaningfully, at least at the starting dose, if the current self-pay figures hold. The tablet is cheaper to start on both NovoCare and GoodRx — $149 a month versus the pen's $199 introductory rate — and that gap holds as doses increase, since the tablet tops out at $299 a month while the pen's standard doses run $349 and the highest strength runs $399. If cost alone is driving the decision and your prescriber is open to either, the tablet is the lower-cost route on both channels.

That said, cost shouldn't be the only input. The pen has the far longer track record — it's the form most of the clinical trial data and years of real-world prescribing are built on. The tablet, approved in December 2025, is newer, and it comes with its own routine: taken once daily, with a roughly 30-minute wait before food or most other medications. Worth discussing with whoever's prescribing, not just picking on price.

Ranked: the cheapest ways to get Wegovy without insurance, if today's prices hold

Pulling the six options above into one ordered list, cheapest to most expensive at the starting dose:

• 1. NovoCare Self-Pay — Wegovy tablet: from $149/mo, no membership fee (unconfirmed, verify before relying on it)
• 2. GoodRx (Wegovy pill): from $149/mo, appears to mirror NovoCare directly
• 3. Mochi Health (compounded semaglutide): ~$178/mo all-in, flat across doses
• 4. Fridays (compounded semaglutide): $150/mo on an annual plan, ~$249/mo month-to-month
• 5. Henry Meds (compounded semaglutide): $249/mo oral, $297/mo injection, all-in
• 6. NovoCare Self-Pay — Wegovy pen: $199/mo introductory, then $349–$399/mo

Notice the tablet and the injection aren't interchangeable on this list — they're different formats of the same brand-name drug, priced differently. If your prescriber has you on the pen specifically, compare it against the pen's own numbers, not the tablet's.

Denied coverage? The appeal path worth trying before you pay cash

Initial denials for GLP-1 weight-management prescriptions are common — insurers reject a large share of first requests, often on paperwork grounds rather than a genuine clinical no. A meaningful share of those denials get reversed on appeal when the documentation is thorough, which makes a first appeal worth the week or two it takes before you commit to a cash-pay plan long-term.

• Ask your insurer for the specific denial reason — missing prior authorization, BMI documentation, or a formulary exclusion each need a different fix.
• Have your prescriber's letter document your BMI, any comorbidities (hypertension, high cholesterol, sleep apnea, type 2 diabetes, cardiovascular disease), and prior attempts at lifestyle-based weight management.
• If your plan has a formulary exclusion rather than a documentation gap, ask HR whether your employer added obesity-medication coverage this year — some large self-insured employers expanded GLP-1 benefits even as others pulled back.
• If the appeal still fails, that's when the self-pay numbers above become your real comparison set, not a fallback.

One thing worth knowing going the other direction: 2026 has also seen some employers narrow GLP-1 coverage further, citing cost, so a plan that covered Wegovy last year isn't guaranteed to cover it this year. Check your current formulary, not what you remember from an earlier renewal. For the full breakdown of the $25 covered-tier mechanics and how prior authorization typically works, see how Wegovy's cost pathways work.

What a full year actually costs, by path

• NovoCare tablet at $149/mo: about $1,788/year — the floor for brand-name Wegovy, if confirmed live.
• Mochi Health at ~$178/mo: about $2,136/year.
• Fridays on the annual plan (~$150/mo): about $1,800/year; month-to-month (~$249/mo): about $2,988/year.
• Henry Meds oral ($249/mo): about $2,988/year; injection ($297/mo): about $3,564/year.
• NovoCare pen at the standard $349/mo maintenance rate: about $4,188/year; at the HD $399/mo rate: about $4,788/year.
• Retail, no program at all ($1,349/mo): about $16,188/year — the number every path above exists to help you avoid.

Red flags when buying Wegovy without insurance online

The more attention GLP-1 drugs get, the more sites try to profit from the confusion between real Wegovy and compounded look-alikes. A few markers separate a legitimate source from one to avoid entirely.

• No prescription required, or a questionnaire that generates a prescription without a licensed clinician actually reviewing it.
• Pricing far below NovoCare's own reported $149–$399 range for an injectable pen, with no explanation of how that's possible.
• No named, verifiable, US-licensed pharmacy behind the product.
• Marketing language like "generic Wegovy" or "FDA-approved compound" — neither is an accurate description of any compounded product.
• Payment requested before any medical review takes place, rather than after a clinician confirms you're a candidate.